Stay updated on Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page
- Check5 days agoChange DetectedA new 'Study Status' entry is added to the Record History, and a new version entry (version 29) appears, reflecting updated status-tracking on the study's history page.SummaryDifference0.3%

- Check12 days agoChange DetectedThe Record History now includes a new revision entry, v3.5.3, replacing the previous v3.5.2 and signifying an updated version of the record.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedAdded a new Study Status entry on 2026-04-03 for revision v3.5.2. Removed the older v3.5.0 revision on 2026-03-02.SummaryDifference0.4%

- Check48 days agoChange DetectedA new revision entry v3.5.0 was added to the history. The previous revision v3.4.3 was removed from the list.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision log updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check70 days agoChange DetectedThe Record History page now includes a Study Status section with new entries on 2026-02-27 and 2026-03-02. The 2026-01-26 entry was removed.SummaryDifference0.3%

Stay in the know with updates to Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.